Terbutil (terbutaline inj/oral): Uses, Dosage & Side Effects

What it's for (Indications)

Terbutaline is a sympathomimetic amine primarily indicated for its bronchodilatory effects.
In its oral formulation, it is used for the prevention and reversal of bronchospasm in patients with bronchial asthma, bronchitis, emphysema, and other chronic obstructive pulmonary diseases (COPD).
The injectable (subcutaneous) form is indicated for the treatment of bronchospasm in adults and children 12 years of age and older with asthma and reversible bronchospasm associated with bronchitis and emphysema.
It provides rapid relief of acute bronchoconstriction.
Terbutaline is a crucial medication for managing respiratory distress by opening airways and improving airflow, thereby alleviating symptoms such as wheezing, shortness of breath, and chest tightness associated with these conditions.
Its use focuses strictly on conditions where bronchodilation is clinically beneficial.

Dosage Information

Type	Guideline
Standard	Dosage of terbutaline varies significantly based on the route of administration (oral versus subcutaneous) and individual patient factors, including age and response to therapy. For oral administration, typical adult dosage for asthma and COPD is 2.5 mg to 5 mg three times a day, not to exceed 15 mg in 24 hours. Pediatric oral dosage is often individualized based on weight or age, typically starting lower. For subcutaneous injection, the usual adult dose is 0.25 mg administered into the lateral deltoid area, which may be repeated once in 15 to 30 minutes if needed, with a maximum dose of 0.5 mg in a 4-hour period. For children aged 12 to 15 years, the subcutaneous dose is generally 0.25 mg, repeated once if necessary. It is crucial to administer the lowest effective dose to minimize potential side effects and to closely monitor patient response. Intravenous administration is generally not recommended for acute bronchospasm.

Type

Guideline

Standard

Dosage of terbutaline varies significantly based on the route of administration (oral versus subcutaneous) and individual patient factors, including age and response to therapy. For oral administration, typical adult dosage for asthma and COPD is 2.5 mg to 5 mg three times a day, not to exceed 15 mg in 24 hours. Pediatric oral dosage is often individualized based on weight or age, typically starting lower. For subcutaneous injection, the usual adult dose is 0.25 mg administered into the lateral deltoid area, which may be repeated once in 15 to 30 minutes if needed, with a maximum dose of 0.5 mg in a 4-hour period. For children aged 12 to 15 years, the subcutaneous dose is generally 0.25 mg, repeated once if necessary. It is crucial to administer the lowest effective dose to minimize potential side effects and to closely monitor patient response. Intravenous administration is generally not recommended for acute bronchospasm.

Safety & Warnings

Common Side Effects

Terbutaline, like other beta-adrenergic agonists, can cause a range of side effects due to its systemic absorption and action on beta-adrenergic receptors.
Common adverse effects include tremor, nervousness, dizziness, headache, palpitations, tachycardia (increased heart rate), and muscle cramps.
Gastrointestinal disturbances such as nausea and vomiting may also occur.
Less common but more serious side effects can involve the cardiovascular system, manifesting as arrhythmias, angina (chest pain), and hypertension.
Hypersensitivity reactions, including paradoxical bronchospasm (worsening of breathing), urticaria, and angioedema, are rare but possible.
Metabolic effects like transient hypokalemia (low potassium levels) and hyperglycemia (elevated blood glucose) have been reported, especially with higher doses or in susceptible individuals.
Patients should be advised to report any persistent or severe side effects to their healthcare provider promptly.

Serious Warnings

Black Box Warning: Terbutaline sulfate, particularly the injectable form, carries significant safety concerns that warrant a strong warning, especially concerning its historical use in obstetrics. The U.S. Food and Drug Administration (FDA) has specifically cautioned against the use of terbutaline sulfate injection in pregnant women for the prevention or prolonged treatment (beyond 48-72 hours) of preterm labor, whether in inpatient or outpatient settings. This strict recommendation stems from documented reports of serious maternal cardiac adverse events, including maternal death. Furthermore, oral terbutaline sulfate is explicitly not recommended for any type of prevention or treatment of preterm labor in pregnant women due to similar potential for severe maternal cardiovascular complications. While not formally designated as a "Black Box Warning" for all indications, this FDA communication serves as a critical safety alert that clinicians must stringently adhere to. Its use should be restricted to acute, short-term management of bronchospasm when alternative therapies are unavailable or inadequate, and never for prolonged tocolysis. Patients should be carefully monitored for cardiovascular adverse effects during and after administration.
Terbutaline carries several important warnings due to its pharmacological profile.
Cardiovascular effects, including dose-related increases in heart rate, palpitations, and blood pressure, may occur.
Caution is advised in patients with pre-existing cardiovascular disorders such as coronary artery disease, cardiac arrhythmias, and hypertension.
It can exacerbate diabetes mellitus or ketoacidosis, requiring close monitoring of blood glucose levels in diabetic patients.
Terbutaline can cause hypokalemia, which may have clinical significance, particularly in patients receiving concomitant diuretics or corticosteroids.
Paradoxical bronchospasm, which is life-threatening, can occur with inhaled or systemic administration and necessitates immediate discontinuation.
Terbutaline should not be used as the sole therapy for asthma, and its prolonged use for tocolysis (preterm labor) has been associated with serious maternal cardiac events and is generally discouraged by regulatory bodies.
Patients should be educated on proper administration and to seek medical attention if their condition worsens or if they experience severe side effects.

How it Works (Mechanism of Action)

Terbutaline is a selective beta-2 adrenergic receptor agonist. Its primary mechanism of action involves stimulating beta-2 adrenergic receptors located predominantly in the smooth muscle of the bronchi, uterus, and vascular beds. Upon binding to these receptors, terbutaline activates adenylyl cyclase, an enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP). The increased intracellular levels of cAMP lead to the activation of protein kinase A, which in turn phosphorylates various intracellular proteins. This phosphorylation cascade ultimately results in the relaxation of bronchial smooth muscle, thereby causing bronchodilation and improving airflow in the respiratory tract. Furthermore, terbutaline also exerts a modest inhibitory effect on the release of inflammatory mediators from mast cells and reduces microvascular permeability. Its selectivity for beta-2 receptors minimizes, but does not eliminate, stimulation of beta-1 receptors in the heart, contributing to its therapeutic utility in respiratory conditions.